New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 7, 2013
10:38 EDTGWPHGW Pharmaceuticals soars after analyst nearly triples price target
Shares of Britain's GW Pharmaceuticals (GWPH) are jumping after a Lazard Capital analyst wrote that the company has one of the most compelling opportunities he's ever seen, and nearly tripled his price target on the stock. WHAT'S NEW: GW's CBD, a drug derived from the cannabis plant, has significantly helped some epilepsy patients to whom it has been administered, Lazard Capital analyst Joshua Schimmer wrote in a note to investors earlier today. Although not all the refractory childhood seizure patients who have taken the drug have improved, evidence suggests that the treatment does have "an antiseizure effect," the analyst believes after speaking with multiple experts. Moreover, "there is an enormous unmet need" for such an antiseizure treatment, and specialists appear to be extremely interested in CBD, Schimmer contended. He hiked his price target on GW to $65 from $22, and kept a Buy rating on the shares. TODAY'S PRICE ACTION: In mid-morning trading, GW rallied $5.95, or 24%, to $30.65.
News For GWPH From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 26, 2015
08:30 EDTGWPHGW Pharmaceuticals risk/reward favorable into data, says Leerink
Leerink says the risk/reward on shares of GW Pharmaceuticals is favorable into the Epidiolex update at AAN on April 22 despite the 34% rally since the last update in October. The firm notes its price target of $102 assumes a 66% probability-of-success for Epidiolex in Dravet/Lennox Gastaut. Changing the probabilities to 100% yields a target of $182, Leerink notes. It reiterates an Outperform rating on GW.
March 17, 2015
07:20 EDTGWPHBofA/Merrill to hold a conference
Smid Cap Conference 2015 is being held in Boston on March 17-18.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use